Category Archives: pricing

"Sunshine" Just the Tip of the Iceberg: Pharma and Full Disclosure

By Jill Wechsler | Published: April 10, 2013

“Sunshine” Just the Tip of the Iceberg: Full Disclosure for Pharma:??There seems no end to demands for data on clinical research, conflicts of interest, company payments, and drug prices, writes Jill Wechsler. Although recent legislation and regulations have greatly expanded the range of information that pharmaceutical companies have to unveil to the public, there’s an escalating [...]

Also posted in Guest Blog, Op-Ed, Regulatory, Safety, Strategy, healthcare | Tagged drug safety, Obamacare, regulatory affairs, Sunshine Act, transparency | 1 Comment

The Patent Black Label: Six Side-Effects of India's Novartis Glivec Ruling

By William Looney | Published: April 3, 2013

Monday’s decision by India’s Supreme Court to deny a patent for the top-selling oncologic drug Glivec took nearly a decade of litigation to resolve – but the implications in and beyond India are both immediate and lasting. Here’s a list of six that Pharm Exec thinks are most important:

Also posted in Emerging Markets, Global, IP, Legal, Manufacturing, Market Access, Strategy | Tagged China, Glivec, Global IP, india, Novartis, oncologics, Patent, Supreme Court, TRIPs | 6 Comments

For Becton Dickinson, Medication Errors are a Business Opportunity

By Ben Comer | Published: April 1, 2013

Over the next few years, med tech company Becton Dickinson will launch up to 30 generic, pre-filled syringes in an attempt to lower medication errors and raise company revenues, according to BD Rx president Mark Sebree. One man’s goof is another man’s growth, potentially.

Also posted in FDA, Manufacturing, R&D, Safety, Strategy, Technology | Tagged Becton Dickinson and Company, Medical Devices, medical supplies, medication error, payers, pre-filled syringes | Leave a comment

Refilling the Antibiotic Pipeline: How to Lead the Horse to Water?

By Clark Herman | Published: March 15, 2013

Last week, the United States Center for Disease Control (CDC) and Britain’s Chief Medical Officer issued separate warnings about the urgent problem of antibiotic resistance in infectious diseases. Given industry’s general lack of interest in developing new antibiotics to address this problem, the warnings indicate that a discussion is needed around which incentives and regulatory [...]

Also posted in FDA, Global, Market Access, R&D, Regulatory, Safety, Strategy | Tagged Antibiotics, CDC, GAIN Act, IDSA, LPAD | 1 Comment

Part D Politics: Medicare Drug Rebates or Price Controls?

By Jill Wechsler | Published: February 20, 2013

Jill Wechsler Blog – PE Feb. 22, 2013 Part D Politics: Medicare drug rebates or price controls? While health care was barely mentioned in the recent State of the Union address, President Obama generated some interest in his proposal to cut Medicare spending by reducing “taxpayer subsidies to prescription drug companies.” That’s code for requiring pharma marketers to pay [...]

Also posted in Op-Ed, Regulatory, healthcare | Tagged Medicare, Obama, Part D, pricing, State of the Union address | Leave a comment